PBH Health LLC does not promote compounded medications as equivalent to or substitutes for FDA-approved drugs. All treatment decisions are made by licensed providers based on individual patient needs.

GLP-1 Updates & Regulatory Compliance

Our Commitment to Safe, Accurate, and Compliant Care

PBH Health LLC is committed to providing patients with accurate, transparent, and medically appropriate information regarding GLP-1 therapies. We actively monitor regulatory guidance and align our clinical and communication practices with current standards established by the U.S. Food and Drug Administration (FDA).

Important Update on Compounded GLP-1 Medications (February 2026)

In February 2026, the FDA issued guidance regarding non-FDA-approved GLP-1 medications, including compounded products. In accordance with this guidance, PBH Health LLC maintains the following standards:

Compounded GLP-1 medications are not FDA-approved
Compounded medications are not represented as equivalent to or substitutes for FDA-approved drugs
PBH Health LLC does not describe compounded medications as “generic” versions of FDA-approved products
PBH Health LLC does not claim that compounded medications produce the same clinical outcomes as FDA-approved medications

How PBH Health LLC Ensures Compliance

To ensure ongoing compliance and patient safety, PBH Health LLC has implemented the following safeguards:

Clinical Oversight

All treatment decisions are made by licensed healthcare providers based on individualized medical evaluation
Prescriptions are issued only when medically appropriate and supported by clinical criteria

Clear Patient Communication

Patients are informed when a medication is FDA-approved versus compounded
All communications avoid misleading or comparative claims

Standardized Medical Documentation

Providers use structured documentation that includes required disclosures regarding compounded medications
Compliance language is standardized and consistently applied

Content Review and Monitoring

Website and patient-facing materials are regularly reviewed for regulatory compliance
Updates are made promptly in response to new FDA guidance

Patient-Centered Treatment Approach

GLP-1 therapies may be considered as part of a broader, individualized care plan that includes:

Nutrition and lifestyle modification
Ongoing clinical monitoring
Risk-benefit evaluation specific to each patient

PBH Health LLC does not guarantee outcomes and does not promote any medication as universally appropriate. Treatment recommendations are based solely on clinical judgment and patient-specific needs.

Transparency and Accountability

PBH Health LLC maintains a conservative, compliance-first approach to healthcare communication. Our goal is to ensure that all information provided to patients is:

Accurate
Non-misleading
Appropriately qualified
Consistent with current regulatory guidance

Questions

If you have questions about GLP-1 therapies or your treatment plan, please contact:

PBH Health LLC 

Dr. Pamela Herbert, Medical Director

1111 Pennsylvania Ave SE, Suite 204

Washington, DC 20003

support@pbhhealthllc.com

Phone: 202-240-7159

Fax: 202-449-1044

Last updated October 2026